MedTrace Logo

Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

NCT03387501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-09-08

No results posted yet for this study

Summary

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Conditions

Interventions

DRUG

Plasma rich in growth factors (PRGF-Endoret)

Intrauterine administration of PRGF

Sponsors & Collaborators

  • Sara Rafael Fernandez

    lead OTHER

Principal Investigators

  • Sara Rafael, PhD · Hospital Clinico San Carlos

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-27
Primary Completion
2022-07-26
Completion
2022-07-26

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03387501 on ClinicalTrials.gov